In ovarian cancer, Peng et al. discovered that DNMTi enhances the therapeutic effect of anti-PD-L1 by reactivating Th1-type chemokines and increasing T-cell infiltration (Peng et al., 2015). Here, NELFCD is linked to ovarian carcinoma.